KH001

Phase 2Small molecule

HHysensBio Co., Ltd

KH001 is one of 7 small molecule programs targeting Dental Caries. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Dental CariesNot yet recruiting

Dental CariesPhase 2

Not yet recruiting

Competition

Competitive Landscape

7 competitors in Dental Caries

#DrugCompanyPhaseTrials

Zocor

OOrganon and Co

Approved

—2

Peridex

DDexcel Pharma Technologies Ltd.

Approved

—3

Betadine

BBecton, Dickinson and Company

Mycostatin

KH001

1 6

Chlorhexidine Digluconate

GSK

Preclinical

1 7

Vancomycin Hydrochloride

WWake Forest University Health Sciences

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 2Not yet recruiting

Dental Caries

NCT07751016

Clinical

Trials by Indication[1]

Dentin Hypersensitivity3 trials

Phase 2 Study of KH001 in Long-term Relief From Dentin Hypersensitivity

Completed·HHysensBio Co., Ltd·Phase 2·NCT06464939·120 enrolled

A Study to Evaluate the Efficacy and Safety of KH001 in Patients with Dentin Hypersensitivity

Completed·HHysensBio Co., Ltd·Phase 2·NCT06264453·171 enrolled

Evaluation of the Safety and Tolerability of KH001 in Dentin Hypersensitivity Patients

Completed·HHysensBio Co., Ltd·Phase 1/2·NCT04804514·40 enrolled

Dentin Caries1 trial

A Study to Evaluate Physiologic Dentin Regeneration and Safety of KH001 in the Administration of Erupted Wisdom Tooth With Dentin Caries

Completed·BByoung-Moo Seo·Phase 2·NCT06580678·12 enrolled

Dental Caries1 trial

A Randomized, Single-center, Double-blinded, Placebo-controlled, Investigator-initiated Trial to Evaluate the Efficacy and Safety of KH001 in Patients With Deep Dentinal Caries

Not yet recruiting·SSeoul National University Dental Hospital·Phase 2·NCT07751016·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for KH001. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KH001 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KH001. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — HysensBio Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHysensBio Co., Ltd

KH001

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Dentin Hypersensitivity3 trials

Dentin Caries1 trial

Dental Caries1 trial

References

Drug Info

Quick Facts

Related News